Your browser doesn't support javascript.
loading
Exploration of KIR genes and hematological-related diseases in Chinese Han population.
Li, Ye-Mo; Li, Yu-Xia; Hu, Xiao-Zhuang; Li, Dai-Yang; An, Lin; Yuan, Zhi-Yang; Liu, Zhong-Liang; Du, Ke-Ming; Zheng, Zhong-Zheng.
Afiliação
  • Li YM; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Li YX; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Hu XZ; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Li DY; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • An L; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Yuan ZY; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Liu ZL; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Du KM; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China.
  • Zheng ZZ; Shanghai Tissuebank Biotechnology Co, Ltd, Shanghai, China. ZZZ@catb.org.cn.
Sci Rep ; 13(1): 9773, 2023 06 16.
Article em En | MEDLINE | ID: mdl-37328612
ABSTRACT
The function of natural killer (NK) cells has previously been implicated in hematopoietic-related diseases. Killer immunoglobulin-like receptors (KIR) play an important role in NK cells after hematopoietic stem cell transplantation. To explore the immunogenetic predisposition of hematological-related diseases, herein, a multi-center retrospective study in China was conducted, analyzing and comparing 2519 patients with hematopathy (mainly, acute lymphoblastic leukemia, acute myeloid leukemia, aplastic anemia, and myelodysplastic syndrome) to 18,108 individuals without known pathology. Genotyping was performed by polymerase chain reaction with specific sequence primers (PCR-SSP). As a result, we discovered four genes including KIR2DL5 (OR 0.74, 95% CI 0.59-0.93; Pc = 0.0405), 2DS1 (OR 0.74, 95% CI 0.59-0.93; Pc = 0.0405), 2DS3 (OR 0.58, 95% CI 0.41-0.81; Pc = 0.0180), and 3DS1 (OR 0.74, 95% CI 0.58-0.94; Pc = 0.0405) to be protective factors that significantly reduce the risk of aplastic anemia. Our findings offer new approaches to immunotherapy for hematological-related diseases. As these therapies mature, they are promising to be used alone or in combination with current treatments to help to make blood disorders a manageable disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article